Abstract: A coffee puck removal device (10) to remove a coffee puck (24) from a portafilter (20) is disclosed herein. The coffee puck removal device (10) has an open compartment (22) containing the coffee puck (24), the coffee puck (24) having an exposed major outer face (26) and a major inner face (28) when the coffee puck (24) is located in the open compartment (22). The device (10) includes: a body (12) having a rim (14) surrounding an aperture (16), with the rim (14) being configured to engage the portafilter (20), with the open compartment (22) facing the body (12) to inhibit air passing between the portafilter (20) and the rim (14); and a vacuum source (30) to remove air from the aperture (16) so that air pressure applied to the major inner face (28) is greater than air pressure applied to the exposed major outer face (26) so that the coffee puck (24) is removed from the portafilter (20).

Abstract: Provided herein, inter alia, are compositions and methods for treating and/or preventing conditions associated with gut inflammation caused by dysbiosis via use of exogenously administered acid phosphatases or enzymes of the GDA1_CD39 superfamily (such as apyrases).

Abstract: The present invention relates to a composition and a method of preparing or treating food products so as to improve their aroma, flavor, mildness, sweetness, consistency, texture, body, mouth feel, firmness, viscosity, gel fracture, wheying off, structure and/or organoleptic properties, nutrition and/or health benefits. In particular, the present invention provides a composition comprising a live micro-organism, an enzyme produced by said micro-organism and an exopolysaccharide (EPS) produced by the activity of said enzyme.

Abstract: A nucleic acid comprising a nucleotide sequence encoding a lysin, which nucleotide sequence comprises the sequence shown in SEQ ID No. 1 or a variant, homologue or derivative thereof. A novel lysin obtainable from a bacteriophage capable of colonising Clostridium perfringens, and the use thereof as a medicament for the treatment of a disorder associated with pathogenic Clostridium bacteria, for example.

Abstract: A B-subunit of a protein toxin selected from the B-subunit of E. coli heat-labile enterotoxin (EtxB) and the B-subunit of Vibrio cholerae toxin (CtxB) has a therapeutic effect against cell surface-expressed viral antigens and tumour antigens. In particular, the protein toxin may be used to treat an animal body, including human, suffering from a disease or condition associated with Epstein Barr Virus or suffering from neoplasia. The therapeutic agent may, additionally, comprise a cell surface-expressed antigen, for instance an Epstein Barr Virus latent membrane protein.

Abstract: The present invention relates to a process for preparing ascopyrone P, or a derivative thereof, said process comprising the steps of:

Abstract: The present invention discloses sequence information relating to pyranosone dehydratase.

Abstract: The present invention provides an antimicrobial composition for use against a micro-organism selected for Listeria, Salmonella, Bacillus, Saccharomyces, Pseudomonas, Clostridium, Lcatobacillus, Brochothrix, Micrococcus, Yersinia, Enterobacter and Zygosaccharomyces, said composition comprising a cyclic compound having Formula (I), or a derivative thereof, wherein R1 and R2 are independently selected from —OH, ═O, and OR′, wherein R′ is H or —COR″, and R″ is C1-10 alkyl; wherein R3 is a substituent comprising an OH-group, wherein R4 and R5 are each independently selected from a hydrocarbyl group, H, OH or ═O, or represent a bond with an adjacent atom on the ring of the cyclic compound. The invention further relates to a process preventing and/or inhibiting the growth of, and/or killing, micro-organisms in a material, and the use of a cyclic compound having Formula (I).

Abstract: The present invention provides use in medicine of a cyclic compound having Formula I, 1

Abstract: The present invention relates to the purification and characterisation of 1,5-anhydro-D-fructose dehydratase.

Abstract: The present invention relates to the purification and characterisation of ascopyrone P synthase.